Search Results - Derek Weycker
- Showing 1 - 15 results of 15
-
1
-
2
-
3
Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice by Derek Weycker, Mark Hatfield, Aaron Grossman, Ahuva Hanau, Alex Lonshteyn, Anjali Sharma, David Chandler
Published in BMC Cancer (2019-02-01)Get full text
Article -
4
Rates of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia in US clinical practice by Asia Sikora Kessler, Seth J. Baum, Emily Kutrieb, Montserrat Vera Llonch, Alex Lonshteyn, Derek Weycker, Daniel E. Soffer
Published in Lipids in Health and Disease (2025-07-01)Get full text
Article -
5
Predictors of Imminent Risk of Nonvertebral Fracture in Older, High‐Risk Women: The Framingham Osteoporosis Study by Marian T Hannan, Derek Weycker, Robert R McLean, Shivani Sahni, Rebecca Bornheimer, Richard Barron, Thomas G Travison, Douglas P Kiel
Published in JBMR Plus (2019-06-01)Get full text
Article -
6
Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine During Pregnancy for Prevention of Respiratory Syncytial Virus Among Infants in Argentina by Lucila Rey-Ares, Ahuva Averin, Nadia Zuccarino, Celina Guadalupe Vega, Emily Kutrieb, Erin Quinn, Mark Atwood, Derek Weycker, Amy W. Law
Published in Infectious Diseases and Therapy (2024-10-01)Get full text
Article -
7
Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile by Derek Weycker, Ahuva Averin, Linnea Houde, Kevin Ottino, Kimberly Shea, Reiko Sato, Bradford D. Gessner, Kari Yacisin, Daniel Curcio, Elizabeth Begier, Mark Rozenbaum
Published in Infectious Diseases and Therapy (2024-01-01)Get full text
Article -
8
Potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for the prevention of acute respiratory... by Ahuva Averin, Amy W. Law, Derek Weycker, Mark Atwood, Erin Quinn, Jessica E. Atwell, Alejandro Cane, Bradford D. Gessner, Sarah Pugh, Kimberly M. Shea
Published in Expert Review of Vaccines (2025-12-01)Get full text
Article -
9
Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosis by Michael Kreuter, Joyce S. Lee, Argyrios Tzouvelekis, Justin M. Oldham, Philip L. Molyneaux, Derek Weycker, Mark Atwood, Katerina Samara, Klaus-Uwe Kirchgässler, Toby M. Maher
Published in ERJ Open Research (2024-07-01)Get full text
Article -
10
-
11
A formula for predicting emphysema extent in combined idiopathic pulmonary fibrosis and emphysema by Athol U. Wells, Joseph Jacob, Nicola Sverzellati, Gary Cross, Joseph Barnett, Angelo De Lauretis, Katerina Antoniou, Derek Weycker, Mark Atwood, Klaus-Uwe Kirchgaessler, Vincent Cottin
Published in Respiratory Research (2024-01-01)Get full text
Article -
12
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis by Michael S. Schechter, Natalia Sabater-Anaya, Gerry Oster, Derek Weycker, Hongsheng Wu, Emilio Arteaga-Solis, Sukirti Bagal, Lisa J. McGarry, Kate Van Brunt, Jessica Morlando Geiger
Published in Pulmonary Therapy (2023-10-01)Get full text
Article -
13
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions by Mark H. Rozenbaum, Erica Chilson, Raymond Farkouh, Liping Huang, Alejandro Cane, Adriano Arguedas, Maria J. Tort, Vincenza Snow, Ahuva Averin, Derek Weycker, Dhwani Hariharan, Mark Atwood
Published in Infectious Diseases and Therapy (2024-03-01)Get full text
Article -
14
Disparities in invasive pneumococcal disease, pneumonia, and otitis media among US children by comorbidity profile and insurance status by Rotem Lapidot, Rotem Lapidot, Rotem Lapidot, Rotem Lapidot, Ahuva Averin, Derek Weycker, Liping Huang, Jeffrey Vietri, Adriano Arguedas, Alejandro Cane, Alexander Lonshteyn, Mark H. Rozenbaum, Stephen I. Pelton, Stephen I. Pelton
Published in Frontiers in Public Health (2025-07-01)Get full text
Article -
15
Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease by William B. Ershler, MD, Laura M. De Castro, MD, MHSc, Zahra Pakbaz, MD, Aaron Moynahan, MA, Derek Weycker, PhD, Thomas E. Delea, MSIA, Irene Agodoa, MD, Ze Cong, PhD
Published in Current Therapeutic Research (2023-01-01)Get full text
Article
